Recent research highlights pivotal advancements in understanding bone marrow dysfunction in patients with multiple myeloma, a rare but aggressive blood cancer. Studies reveal that the malignant proliferation of plasma cells disrupts normal marrow function, impairing blood cell production and weakening immune defense. Novel therapeutic approaches—including targeted immunotherapies, CAR-T cell treatments, and precision oncology strategies—are showing promising results in improving patient outcomes.